A report from Myeloma UK and the National Institute for Health and Care Excellence (NICE) outlines the findings from a study looking at how patient preferences could be more formally incorporated in health technology assessments (HTA).

Feedback from a patient and family workshop demonstrated how myeloma impacts the lives of patients in different ways and how important it is that these preferences are captured and used. The researchers concluded that the study showed a clear scope for the better use of quantitative patient preference data in health assessments to help ensure new treatments reflect the needs and preferences of patients and family members living with myeloma and other conditions.

Dr Jayne Galinsky, Myeloma UK and project lead said “Patients need access to the most effective treatments and it is important that decision makers understand the benefits and risks of new treatments from a wider patient perspective.  By making recommendations about the right models for incorporating patient preferences into HTA decision making, this study is the next step to ensuring that patients’ voices are properly heard.”

This study is the first step towards the use of quantitative patient preference data to strengthen the patient voice within HTAs.

Read more in PharmaTimes here